Brief: HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents
31/03/2020 12:40
March 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS COMMENTS ON U.S. DISTRICT COURT DECISION
ON
AMARIN PATENTS
* HLS THERAPEUTICS INC - SEEKS TO CLARIFY THAT THIS
LITIGATION AND
JUDGMENT DO NOT IMPACT VASCEPA IN CANADA
Source text for Eikon: ID:nCNW4SqSMa
Further company coverage: HLS.TO
((Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group